We have studied the simultaneous administration of rhG-CSF with doxorubicin, the latter given by continuous infusion either intra-arterially or intravenously, in a group of patients with various sarcomas. This has enabled us to substantially increase the dosage intensity of doxorubicin with a marked decrease in both hematologic and oral toxicity. While the data concerning anti-tumor activity is preliminary we believe that this combination has been responsible for a substantial increase in the effectiveness of doxorubicin in controlling the sarcomas. No adverse effect from combining doxorubicin given by infusion with rhG-CSF has been noted to date.

Related Articles